DiaMedica Therapeutics Inc.
General ticker "DMAC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $226.6M (TTM average)
DiaMedica Therapeutics Inc. follows the US Stock Market performance with the rate: 60.1%.
Estimated limits based on current volatility of 3.2%: low 6.39$, high 6.81$
Factors to consider:
- Total employees count: 28 (+47.4%) as of 2024
- Top business risk factors: Operational and conduct risks, Completing clinical development, Regulatory and compliance, Strategic risks and growth management, Manufacturing scale up
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.89$, 11.72$]
- 2026-12-31 to 2027-12-31 estimated range: [5.15$, 10.53$]
Financial Metrics affecting the DMAC estimates:
- Negative: with PPE of -11.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -7.47 <= 0.07
- Positive: Investing cash flow per share per price, % of -0.56 > -0.65
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 91.43 > 64.25
Short-term DMAC quotes
Long-term DMAC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $21.27MM | $26.68MM | $34.40MM |
| Operating Income | $-21.27MM | $-26.68MM | $-34.40MM |
| Non-Operating Income | $1.93MM | $2.27MM | $1.66MM |
| R&D Expense | $13.11MM | $19.06MM | $24.61MM |
| Income(Loss) | $-19.34MM | $-24.41MM | $-32.74MM |
| Taxes | $0.04MM | $0.03MM | $0.03MM |
| Profit(Loss)* | $-19.38MM | $-24.44MM | $-32.77MM |
| Stockholders Equity | $51.06MM | $40.72MM | $56.11MM |
| Assets | $54.16MM | $46.34MM | $61.37MM |
| Operating Cash Flow | $-18.73MM | $-22.08MM | $-29.06MM |
| Capital expenditure | $0.02MM | $0.03MM | $0.04MM |
| Investing Cash Flow | $-18.30MM | $8.56MM | $-2.19MM |
| Financing Cash Flow | $36.84MM | $11.99MM | $43.88MM |
| Earnings Per Share** | $-0.60 | $-0.60 | $-0.70 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.